Zegfrovy (Sunvozertinib) for Lung Cancer

Overview
Zegfrovy is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific mutations (changes) in the epidermal growth factor receptor (EGFR) gene known as exon 20 insertion mutations. It is used in people whose cancer has progressed after treatment with platinum-based chemotherapy. This approval was granted under the FDA’s accelerated approval pathway based on how well the drug shrank tumors and how long that effect lasted. Continued approval may depend on results from further clinical trials. Zegfrovy is also known by its drug name, sunvozertinib.

Zegfrovy is a kinase inhibitor. It works by blocking abnormal proteins produced by the EGFR exon 20 insertion mutations, which helps slow or stop the growth of cancer cells in the lungs.

How do I take it?
Prescribing information states that Zegfrovy is taken by mouth as a tablet once daily with food. The drug is usually taken once a day on a consistent schedule. Zegfrovy should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Zegfrovy include diarrhea, rash, decreased appetite, stomatitis (mouth sores), fatigue, nausea, paronychia (infection of the skin around the nails), vomiting, constipation, muscle and joint pain, pruritus (itching), dry skin, urinary tract infection, stomach pain, and weight loss.

Rare but serious side effects may include interstitial lung disease (a condition that causes lung inflammation and scarring), severe skin reactions, severe gastrointestinal issues such as prolonged diarrhea or vomiting, and eye problems such as keratitis (inflammation of the cornea). Zegfrovy may also harm an unborn baby if taken during pregnancy.

For more information about this treatment, visit:

Zegfrovy (Sunvozertinib) Tablets, for Oral Use — Dizal (Jiangsu) Pharmaceutical